Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Carbamazepine and oxcarbazepine are both anticonvulsant medications primarily used to treat partial (focal) seizures in epilepsy. Carbamazepine is also indicated for trigeminal neuralgia and bipolar I disorder, while oxcarbazepine is mainly used for seizure control. Oxcarbazepine is a 10-keto derivative of carbamazepine, developed to reduce side effects associated with carbamazepine metabolites. Both drugs act by inhibiting voltage-gated sodium channels in neuronal membranes, stabilizing hyperexcited nerve cells and reducing abnormal electrical activity in the brain. Oxcarbazepine also modulates certain calcium channels differently from carbamazepine[1][4][5][8]. Carbamazepine is metabolized via the cytochrome P450 system, whereas oxcarbazepine undergoes reductive metabolism with minimal involvement of hepatic enzymes[5]. Both drugs are available as generics and under several brand names.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on carbamazepine + oxcarbazepine.